You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: DNATRIX INC            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal

    SBC: BESSOR PHARMA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Cisplatin is a cornerstone therapy for a number of cancers including testicular, bladder, ovarian and lung. It is also used to treat cancers in children. In all cases there is a high incidence of acute kidney injury (AKI) that can also lead to later stage kidney damage. This risk limits its use. We have found in pilot studies that renalase, or peptide fragment ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis

    SBC: DYNUPOL, INC.            Topic: NCI

    Project Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Inhibitors of the STARS/SRF Pathway for Treatment of Type 2 Diabetes

    SBC: Jenesis Biosciences LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Screening for Novel CBS Inhibitors for Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide (H2S) in colorectal cancer: selective upregulation of cystathionine-b-synthase (CBS) and the subsequent production of H2S in colonic cancer cells serves as a pro-survival factor by stimulating tumor cell bioenergetics, growth, proliferation, migratio ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government